DelveInsight’s, “Ataxia-telangiectasia - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Ataxia-telangiectasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

    Geography Covered
    • Global coverage

    Ataxia-telangiectasia Understanding
    Ataxia-telangiectasia: Overview
    Ataxia telangiectasia (AT) is a complex genetic neurodegenerative disorder that may become apparent during infancy or early childhood. Classic AT is characterized by a constellation of clinical symptoms including progressive ataxia, oculocutaneous telangiectasias and sinopulmonary disease and is usually associated with absence of ATM protein. Affected children typically develop difficulty in walking, problems with balance and hand coordination, involuntary jerking movements (chorea), muscle twitches (myoclonus), and disturbances in nerve function (neuropathy). Other laboratory features associated with AT include elevated serum levels of alpha-fetoprotein (AFP) and increased chromosomal breakage with in vitro exposure to ionizing radiation. Treatment for AT is directed toward control of symptoms. For respiratory infections, therapy with an antibiotic drug, postural drainage (with the head lower than the rest of the body) of the bronchial tubes and lungs, and gammaglobulin injections in some cases may be effective.

    "Ataxia-telangiectasia - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ataxia-telangiectasia pipeline landscape is provided which includes the disease overview and Ataxia-telangiectasia treatment guidelines. The assessment part of the report embraces, in depth Ataxia-telangiectasia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ataxia-telangiectasia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.


    Report Highlights
    • The companies and academics are working to assess challenges and seek opportunities that could influence Ataxia-telangiectasia R&D. The therapies under development are focused on novel approaches to treat/improve Ataxia-telangiectasia.

    Ataxia-telangiectasia Emerging Drugs Chapters
    This segment of the Ataxia-telangiectasia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

    Ataxia-telangiectasia Emerging Drugs
    • GTX-102: Acasti Pharma
    GTX-102 is a novel and convenient oral mucosal spray formulation of betamethasone intended to significantly improve neurological symptoms of A-T, including improving clinical assessments of posture and gait disturbance, and kinetic speech and oculomotor functions. The drug is in Phase III clinical studies for the treatment of Ataxia-telangiectasia.
    • IB1001: IntraBio
    IB1001 (N-Acetyl-L-Leucine) is an orally administered small molecule, calcium channel modulator and modified amino acid. IntraBio is developing IB1001 for other neurodegenerative diseases and lysosomal storage disorders. The drug is in Phase II clinical studies for the treatment of Ataxia-telangiectasia.
    Further product details are provided in the report??..

    Ataxia-telangiectasia: Therapeutic Assessment
    This segment of the report provides insights about the different Ataxia-telangiectasia drugs segregated based on following parameters that define the scope of the report, such as:
    • Major Players in Ataxia-telangiectasia
    There are approx. 4+ key companies which are developing the therapies for Ataxia-telangiectasia. The companies which have their Ataxia-telangiectasia drug candidates in the most advanced stage, i.e. Phase III include, Acasti Pharma.
    • Phases
    DelveInsight’s report covers around 4+ products under different phases of clinical development like
    • Late stage products (Phase III)
    • Mid-stage products (Phase II)
    • Early-stage product (Phase I) along with the details of
    • Pre-clinical and Discovery stage candidates
    • Discontinued & Inactive candidates
    • Route of Administration
    Ataxia-telangiectasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
    • Oral
    • Parenteral
    • Intravitreal
    • Subretinal
    • Topical
    • Molecule Type
    Products have been categorized under various Molecule types such as
    • Monoclonal Antibody
    • Peptides
    • Polymer
    • Small molecule
    • Gene therapy
    • Product Type
    Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

    Ataxia-telangiectasia: Pipeline Development Activities
    The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Ataxia-telangiectasia therapeutic drugs key players involved in developing key drugs.

    Pipeline Development Activities
    The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ataxia-telangiectasia drugs.

    Ataxia-telangiectasia Report Insights
    • Ataxia-telangiectasia Pipeline Analysis
    • Therapeutic Assessment
    • Unmet Needs
    • Impact of Drugs

    Ataxia-telangiectasia Report Assessment
    • Pipeline Product Profiles
    • Therapeutic Assessment
    • Pipeline Assessment
    • Inactive drugs assessment
    • Unmet Needs

    Key Questions
    Current Treatment Scenario and Emerging Therapies:
    • How many companies are developing Ataxia-telangiectasia drugs?
    • How many Ataxia-telangiectasia drugs are developed by each company?
    • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ataxia-telangiectasia?
    • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ataxia-telangiectasia therapeutics?
    • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
    • What are the clinical studies going on for Ataxia-telangiectasia and their status?
    • What are the key designations that have been granted to the emerging drugs?

    Key Players
    • Acasti Pharma
    • EryDel
    • IntraBio
    • Matrix Biomed

    Key Products
    • GTX-102
    • Ery-Dex
    • IB1001
    • MBM-01